Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EDGENASDAQ:KZIANASDAQ:OHRPNASDAQ:ONTXNASDAQ:RGLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDGEEdge Therapeutics$3.25+1.6%$4.11$0.28▼$17.38$102.41M3.65373,201 shs445,770 shsKZIAKazia Therapeutics$0.39-2.5%$0.30$0.19▼$1.43$6.45M2.12406,784 shs103,928 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs21,218 shsONTXOnconova Therapeutics$0.83$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsRGLSRegulus Therapeutics$2.22-1.8%$2.17$1.08▼$3.79$147.95M1.57375,438 shs91,807 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDGEEdge Therapeutics+7.02%+14.29%-32.35%-39.62%-47.88%KZIAKazia Therapeutics-1.52%+13.38%+45.15%+5.28%-70.66%OHRPOHR Pharmaceutical0.00%+0.26%-57.90%-30.07%+197.53%ONTXOnconova Therapeutics0.00%0.00%+13.36%+47.89%-15.65%RGLSRegulus Therapeutics-1.77%-5.13%-21.28%+74.80%+63.24%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDGEEdge TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics0.7065 of 5 stars3.53.00.00.00.00.00.0RGLSRegulus Therapeutics2.3752 of 5 stars4.42.00.00.02.01.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDGEEdge TherapeuticsN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideRGLSRegulus Therapeutics2.80Moderate Buy$7.25226.58% UpsideCurrent Analyst RatingsLatest RGLS, EDGE, ONTX, OHRP, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDGEEdge TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AKZIAKazia Therapeutics$20K317.81N/AN/A$0.50 per share0.78OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDGEEdge Therapeutics-$40.86MN/A0.00∞N/AN/A-81.29%-56.92%N/AKZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)Latest RGLS, EDGE, ONTX, OHRP, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDGEEdge TherapeuticsN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDGEEdge TherapeuticsN/A5.595.59KZIAKazia TherapeuticsN/A0.71N/AOHRPOHR PharmaceuticalN/A3.733.73ONTXOnconova TherapeuticsN/A2.792.79RGLSRegulus TherapeuticsN/A3.313.31OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDGEEdge Therapeutics28.04%KZIAKazia Therapeutics30.89%OHRPOHR Pharmaceutical10.70%ONTXOnconova Therapeutics7.95%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipEDGEEdge Therapeutics37.10%KZIAKazia Therapeutics1.00%OHRPOHR Pharmaceutical12.50%ONTXOnconova Therapeutics3.30%RGLSRegulus Therapeutics8.41%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEDGEEdge TherapeuticsN/A31.51 millionN/ANot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableRGLSRegulus Therapeutics3065.46 million59.96 millionOptionableRGLS, EDGE, ONTX, OHRP, and KZIA HeadlinesSourceHeadlineRegulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $1.61americanbankingnews.com - April 24 at 3:44 AMRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDseekingalpha.com - April 10 at 1:50 PMBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needsmarkets.businessinsider.com - March 28 at 2:29 PMShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%marketbeat.com - March 27 at 10:53 AMBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestonesmarkets.businessinsider.com - March 26 at 3:28 AMRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 25 at 8:21 AMRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancementsfinance.yahoo.com - March 23 at 10:30 AMRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinanznachrichten.de - March 22 at 7:21 AMRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 11:00 PMRegulus: Q4 Earnings Snapshottimesunion.com - March 21 at 9:20 PMRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinance.yahoo.com - March 21 at 4:20 PMBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Datamarkets.businessinsider.com - March 19 at 11:39 PMRGLS Mar 2024 7.500 putfinance.yahoo.com - March 15 at 5:16 AMBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & Morefinance.yahoo.com - March 14 at 2:15 PM$100 million fundraise for antisense firm working in nephrologythepharmaletter.com - March 13 at 7:40 PMRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Positionmarkets.businessinsider.com - March 13 at 2:40 PMRegulus (RGLS) Up 71% on Topline Data from Kidney Disease Studyzacks.com - March 13 at 1:11 PMRegulus Therapeutics Shares Soar on Funding, Study Datamarketwatch.com - March 12 at 7:11 PMRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mlnmarkets.businessinsider.com - March 12 at 2:10 PMWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?msn.com - March 12 at 2:10 PMRegulus cues up $100m placement on ADPKD drug datapharmaphorum.com - March 12 at 9:10 AMConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bellmsn.com - March 12 at 9:10 AMRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429markets.businessinsider.com - March 12 at 9:10 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentBanks Think Small Cap Stocks Need to Catch Up: 3 WinnersApril 3, 2024 8:54 AMView Banks Think Small Cap Stocks Need to Catch Up: 3 Winners3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsEdge TherapeuticsNASDAQ:EDGEPDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.